CHU Toulouse Larrey, CEREMAST, Service de Dermatologie et Allergologie cutanée

Toulouse 31059

0 studies enrolling now · 1 studies all time

What they study most

Indolent Systemic Mastocytosis

Studies at this site

• (PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic Mastocytosis — Running, not enrolling